Crescent Biopharma (CBIO) Other Non-Current Assets (2015 - 2026)
Crescent Biopharma (CBIO) posted quarterly Other Non-Current Assets of $1.5 million for Q2 2026, up 1313.21% year-over-year from $106000.0 in Q2 2025, and up 29.25% quarter-over-quarter from $1.2 million in Q1 2026.
Crescent Biopharma (CBIO) Other Non-Current Assets (2015 - 2026) Analysis & Trends
Crescent Biopharma (CBIO) has reported Other Non-Current Assets for 13 consecutive years, with $1.5 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Other Non-Current Assets rose 1313.21% year-over-year to $1.5 million; the TTM figure through Jun 2026 stood at $1.5 million (up 1313.21% YoY), while the FY2025 annual figure was $1.2 million, up 49.57% from the prior year.
- Other Non-Current Assets grew to $1.5 million in Q2 2026 per CBIO's latest filing, from $1.2 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $2.2 million in Q1 2022 and bottomed at $52320.0 in Q1 2023.
- Historically, Other Non-Current Assets has averaged $748983.2 across 5 years, with a median of $603737.0 in 2023.
- Annual changes were most pronounced in 2023 — Other Non-Current Assets sank 97.64% — and 2025, when it soared 2294.88%.
- Crescent Biopharma's Other Non-Current Assets stood at $294710.0 in 2022, then soared by 104.86% to $603737.0 in 2023, then jumped by 34.66% to $813000.0 in 2024, then soared by 49.57% to $1.2 million in 2025, then climbed by 23.19% to $1.5 million in 2026.
- Business Quant data shows CBIO's Other Non-Current Assets at $1.5 million in Q2 2026, $1.2 million in Q1 2026, and $1.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Crescent Biopharma | 1.10 Bn | 933.02 Mn | - | 1.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.50 Mn |
| Mar 31, 2026 | 1.16 Mn |
| Dec 31, 2025 | 1.22 Mn |
| Sep 30, 2025 | 1.25 Mn |
| Jun 30, 2025 | 106,000.00 |
| Dec 31, 2024 | 813,000.00 |
| Sep 30, 2024 | 52,320.00 |
| Jun 30, 2024 | 137,105.00 |
| Mar 31, 2024 | 192,268.00 |
| Dec 31, 2023 | 603,737.00 |
| Sep 30, 2023 | 50,000.00 |
| Jun 30, 2023 | 52,320.00 |
| Mar 31, 2023 | 50,000.00 |
| Dec 31, 2022 | 294,710.00 |
| Sep 30, 2022 | 807,800.00 |
| Jun 30, 2022 | 2.22 Mn |
| Mar 31, 2022 | 52,320.00 |
| Dec 31, 2021 | 52,320.00 |
| Sep 30, 2021 | 1.56 Mn |
| Jun 30, 2021 | 52,320.00 |